Study on the risk of cholangitis induced by immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System

Zhao Yanyan, Zhang Huixian, Meng Luhua, Feng Jianbo

PDF(360 KB)
PDF(360 KB)
Adverse Drug Reactions Journal ›› 2022, Vol. 24 ›› Issue (8) : 424-429. DOI: 10.3760/cma.j.cn114015-20220207-00099

Study on the risk of cholangitis induced by immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 24(8): 424-429 https://doi.org/10.3760/cma.j.cn114015-20220207-00099

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(360 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉